Novocure Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
NovoCure Ltd. (NVCR) PT Raised to $59 at Wedbush
March 1, 2019 11:24 AM ESTWedbush analyst David Nierengarten raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $59.00 (from $55.00) while maintaining a Outperform rating.
... MoreNovocure (NVCR) Misses Q4 EPS by 4c, Revenues Miss
February 28, 2019 6:14 AM ESTNovocure (NASDAQ: NVCR) reported Q4 EPS of ($0.17), $0.04 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $69.7 million versus the consensus estimate of $71.42 million.
Quarterly net revenues of $69.7 million, representing 30 percent growth versus the fourth quarter 2017 and 8 percent growth versus the third quarter 2018Full... More